Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
The full schedule hits maximum dose at approximately week 21
The primary outcome assessed was the change in HbA1c levels from baseline to week 40 ( 4.3 SURPASS-3 trial comparison of tirzepatide and insulin degludec The SURPASS-3 trial involved 1,444 patients with type 2 diabetes who had HbA1c levels ranging from 7% to 10.5% and a BMI of 25 kg/m 2 or higher
Haematologica 105:13691378
Hoornweg, T
119 MariM.MoralesA.ColellA.Garcia-RuizC.KaplowitzN.Fernandez-ChecaJ
US$ 29.63
US$ 24.65
US$ 20.06
US$ 26.70
US$ 27.52
US$ 26.29
